Kineret Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kineret market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to the increasing prevalence of autoimmune diseases, advancements in biological therapies, FDA approvals and regulatory support, improvements in patient adherence, and greater awareness and diagnosis.

The anticipated growth during the forecast period is driven by the rising use of biologics, the expansion of indications, increased healthcare spending, technological advancements in drug delivery, and the growing geriatric population. Key trends during this period include regulatory progress, the development of biosimilars, personalized medicine, market expansion in emerging regions, and a shift towards home-based self-administration.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the kineret market in the future. Autoimmune diseases are a group of disorders where the immune system mistakenly attacks the body’s own cells, tissues, and organs, perceiving them as foreign threats. The rising occurrence of autoimmune diseases can be linked to a combination of genetic, environmental, and lifestyle factors. Kineret, a medication particularly effective in treating autoimmune diseases, helps manage conditions involving excessive inflammation caused by the immune system's attack on the body’s tissues. For example, in May 2023, the National Institute for Health and Care Research (NIHR), a UK-based health research organization, reported that autoimmune disorders now affect approximately one in ten people. Their study of 22 million individuals found that 19 autoimmune diseases impact about 10% of the population, including 13% of women and 7% of men. As a result, the increasing prevalence of autoimmune diseases is fueling the growth of the kineret market.

The rising incidence of inflammatory diseases is another factor driving the growth of the kineret market. Inflammatory diseases involve an abnormal immune response that leads to chronic or acute inflammation in tissues or organs. The increasing occurrence of these conditions is attributed to factors such as an aging population, heightened exposure to environmental pollutants, and lifestyle behaviors including poor diet, sedentary habits, and smoking. Kineret (anakinra) is effective in managing inflammatory diseases by inhibiting interleukin-1 (IL-1), a key protein involved in inflammation. For instance, in 2023, Crohn's and Colitis Canada, a Canadian non-profit organization, reported that the number of people in Canada with IBD is rising rapidly, growing from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). In 2023 alone, 11,000 individuals were diagnosed with IBD (1 every 48 minutes), a figure projected to rise to 14,000 by 2035 (1 every 38 minutes). Consequently, the rising prevalence of inflammatory diseases is boosting the kineret market's growth.

A key trend in the kineret market is the adoption of strategic partnerships to develop innovative Kineret-based products and gain a competitive edge. Such collaborations enable companies in the Kineret market to combine resources and expertise, enhance research and development efforts, expand their market presence, and accelerate product commercialization, fostering industry innovation and growth. For example, in May 2024, Swedish Orphan Biovitrum AB, a Sweden-based biopharmaceutical company, partnered with Handok Inc., a South Korea-based pharmaceutical company, to introduce Kineret (anakinra) in South Korea. This partnership leverages Handok's local expertise alongside Sobi's global biopharmaceutical capabilities, particularly in addressing rare diseases.

The key company operating in the kineret market is Sobi (Swedish Orphan Biovitrum AB)

North America was the largest region in the kineret market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kineret report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kineret market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kineret is the brand name for anakinra, a prescription medication primarily used to treat various inflammatory conditions. It is a recombinant version of the human interleukin-1 receptor antagonist (IL-1Ra), which works by blocking the action of interleukin-1 (IL-1), a protein involved in inflammation and immune responses.

The main indication types of kineret are treatment of rheumatoid arthritis, treatment of Still's disease, treatment of cryopyrin-associated periodic syndromes, and treatment of neonatal-onset multisystem inflammatory disease (NOMIDN). Rheumatoid arthritis is an autoimmune condition that leads to chronic inflammation, pain, and swelling in the joints, potentially causing joint damage and disability. Available formulations include injectable forms (subcutaneous), pre-filled syringes, and auto-injectors. The patient population includes pediatric, adult, and geriatric patients. Distribution occurs through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and wholesalers. It is used by different healthcare providers, including hospitals, specialty clinics, outpatient treatment centers, and home healthcare services.

The kineret market research report is one of a series of new reports that provides kineret market statistics, including kineret industry global market size, regional shares, competitors with a kineret market share, detailed kineret market segments, market trends and opportunities, and any further data you may need to thrive in the kineret industry. This kineret market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kineret market consists of sales of pre-filled syringes and auto-injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.